Sydney, Australia 3 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, wishes to address recent enquiries made to the company and in the media1,2,3 regarding the outage at the High Flux Reactor (HFR) in Petten, Netherlands. On 24 January 2022, the Nuclear…
Sydney, Australia 1 February 2022 Cohort 1 completed in 3 participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 75MBq/kg body weight No dose limiting toxicities (DLTs) have been reported in cohort 1 The Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned Recruitment…
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to release its first Annual Newsletter as a listed entity for the calendar year ending 31 December 2021. To read the Year in Review 2021 Newsletter, click here, About Clarity Clarity is a…
Sydney, Australia 2 December 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered into an agreement covering Clarity’s Targeted Copper Theranostics (TCT) platform. Cardinal Health will provide cGMP product manufacturing…
Sydney, Australia 1 December 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic 64Cu SAR-bisPSMA clinical trial (PROPELLER) in patients with untreated, confirmed prostate…
Sydney, Australia 26 November 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the patent application covering formulations of Clarity’s optimised Prostate Specific Membrane Antigen (PSMA) targeting agent, SAR-bisPSMA, has entered the national phase…
Sydney, Australia 16 November 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce the launch of a partnership with Story Factory, a not-for-profit creative writing centre for young people in under-resourced communities across Sydney and…
Sydney, Australia 10 November 2021 Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)1 investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). Dosimetry data is being prepared for Safety Review Committee before moving into therapeutic applications with 67Cu SAR-bisPSMA therapy. Clarity shares…
Sydney, Australia 19 October 2021 C-BOBCAT breast cancer trial of Clarity’s SAR-Bombesin product closes for recruitment. The diagnostic program with 64Cu SAR-Bombesin generated evidence of the utility and potential superiority in some patient subgroups compared to conventional imaging (e.g. 99mTc bone scan, 18F FDG). The high uptake and strong product retention visualised by PET imaging…
30 September 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc. (“Evergreen”), a radiopharmaceutical contract manufacturer, are pleased to announce that the companies have entered into a Targeted Copper Theranostics (TCTs) manufacturing agreement for Clarity’s US clinical trials.…